- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.11.25 | Alkermes prevails over Lundbeck in Avadel bidding war | ||
| 19.11.25 | Arrowhead nets first commercial win as siRNA drug garners FDA approval | ||
| 19.11.25 | FDA approves AbbVie's Epkinly to treat follicular lymphoma | ||
| 19.11.25 | CSL to pump $1.5bn into US plasma supply chain | ||
| 19.11.25 | USPTO grants patent to Genprex's Reqorsa gene therapy | ||
| 19.11.25 | Insmed receives EC approval for Brinsupri to treat NCFB | ||
| 18.11.25 | Redefining clinical trials in oncology and rare diseases across the Europe | ||
| 18.11.25 | Solve Therapeutics raises $120m as MSD joins list of backers | ||
| 18.11.25 | Merus and Halozyme link on subcutaneous petosemtamab | ||
| 18.11.25 | Johnson & Johnson to acquire Halda Therapeutics for $3.05bn | ||
| 17.11.25 | Henlius and Organon score first US Perjeta biosimilar approval | ||
| 17.11.25 | High-dose Spinraza inches closer to EU approval despite FDA setback | ||
| 17.11.25 | Medicxi unveils €500m fund for asset-centric biotechs | ||
| 17.11.25 | FDA approves Sarepta's updated Elevidys label for DMD | ||
| 17.11.25 | Sofinnova closes €650m healthcare fund for early-stage ventures | ||
| 14.11.25 | MSD bets big on flu antivirals with $9.2bn buyout of Cidara | ||
| 14.11.25 | Eli Lilly and Novo Nordisk disown Mangoceuticals' GLP-1RA partnership claim | ||
| 14.11.25 | Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy | ||
| 14.11.25 | General Proximity and Daiichi Sankyo link on oncology | ||
| 14.11.25 | Eisai and Biogen report Leqembi's MHRA approval for Alzheimer's | ||
| 13.11.25 | Metagenomi culls 25% of its workforce and replaces CEO in reshuffle | ||
| 13.11.25 | FDA unveils new pathway to usher bespoke therapies to market | ||
| 13.11.25 | EuropaBio calls for "bold approach to investment" amid EU Biotech Act | ||
| 13.11.25 | CPHI 2025: 'handprint' metric bridges pharma sustainability and economic value | ||
| 13.11.25 | Chiesi and Aliada sign licence deal for enzyme replacement therapies |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .